Volume 27.2 of the JMCM is now available. FEATURED ARTICLES INCLUDE: Implementing New Data and Evolving Standards in HER2-Negative Breast Cancer: Expert Strategies on the Expanding Role of Targeted Therapy; Innovative Approaches in the Treatment and Management of Heart Failure: Managed Care Considerations on the Role of New and Emerging Therapies; Managed Care Considerations in the Management of Amyotrophic Lateral Sclerosis: A Closer Look at the Emerging Role of Oral Therapy Options
Current Issue Article:
Implementing New Data and Evolving Standards in HER2-Negative Breast Cancer: Expert Strategies on the Expanding Role of Targeted Therapy
APPROXIMATELY 300,000 CASES OF BREAST cancer are diagnosed annually in the United States.1 Hormone receptor positive disease is the most common type followed by human epidermal growth factor receptor two (HER2) positive, and then triple- negative breast cancer. Between 5 percent and 10 percent of all cases will be in patients with a breast cancer (BRCA) gene mutation.
Click Here…